Содержание
- 2. Congress Overview EASL 2017 data provides further evidence for the emerging treatment paradigm to establish 8
- 3. Outline: EASL 2017 Highlights
- 4. DAA-Naive ± Cirrhosis
- 5. Executive Summary Emerging treatment paradigm to establish 8 weeks of treatment for TN NC, across all
- 6. GS-007, Foster: ENDURANCE-3: Safety and Efficacy of G/P Compared to SOF + DCV in Treatment-Naive HCV
- 7. SAT-233, Puoti: High SVR Rates with 8 and 12 Weeks of Pangenotypic G/P: Integrated Efficacy Analysis
- 8. SAT-233, Puoti: High SVR Rates with 8 and 12 Weeks of Pangenotypic G/P: Integrated Efficacy Analysis
- 9. FRI-238, Dufour: Safety of G/P in Adults with Chronic GT1–6 HCV Infection: An Integrated Analysis d/c,
- 10. GS-006, Forns: EXPEDITION-I: Efficacy and Safety of G/P for Treatment of Chronic HCV GT1, 2, 4,
- 11. THU-263, Gane: Pharmacokinetics and Safety of G/P in Adults with chronic GT1–6 HCV Infection and Compensated
- 12. FRI-205, Krishnan: Pooled Resistance Analysis in HCV GT1–6-Infected Patients Treated with G/P in Phase 2 and
- 13. FRI-262, Chayama: CERTAIN-1: Efficacy and Safety of G/P in Japanese Patients with Chronic Genotype 1 Hepatitis
- 14. FRI-263, Chayama: Efficacy and Safety of G/P in Japanese Patients with Chronic Genotype 2 Hepatitis C
- 15. THU-273, Lawitz: Treatment with SOF/VEL or SOF/VEL/VOX is Well Tolerated and Results in High SVR12 in
- 16. SAT-280, Roberts: SOF/VEL/VOX Results in High SVR12 Rates When Administered for 12 Weeks in DAA-experienced Patients
- 17. THU-257, Wyles: No Impact of RASs on the High Efficacy of SOF/VEL/VOX for 8 Weeks in
- 18. SAT-236, Manns: The Safety and Tolerability of SOF/VEL/VOX for 8 or 12 Weeks in >1,000 Patients
- 19. FRI-213, Foster: EBR/GZR + SOF ± RBV in Treatment-Naive and Treatment-Experienced Cirrhotic People with HCV GT3
- 20. THU-249, Hezode: Efficacy and Safety of SOF and DCV for 8 Weeks in Treatment-Naive Non-Cirrhotic Patients
- 21. THU-258, Troland: 12 Weeks of SOF, DCV and RBV for GT3 Patients with Cirrhosis CP, Child
- 22. DAA-Experienced
- 23. Executive Summary Patients who have failed a DAA-containing regimen are a minority population (~5–10%), however there
- 24. PS-156, Poordad: MAGELLAN-1, PART 2: G/P for 12 or 16 Weeks in Patients with Chronic HCV
- 25. SAT-204, Pilot-Matias: Resistance Analysis in the MAGELLAN-1 Study (Part 2): G/P Therapy in HCV-Infected Patients Who
- 26. THU-305, Ng: Resistance Selection Using GLE and PIB in Replicons of Major HCV Genotypes * Relative
- 27. SAT-280, Roberts: SOF/VEL/VOX Results in High SVR12 Rates When Administered for 12 Weeks in DAA-experienced Patients
- 28. THU-248, Sarrazin: No Impact of RASs on the High Efficacy of SOF/VEL/VOX for 12 Weeks in
- 29. * Patients with BL RAS testing results. PS-155, Vermehren; High SVR Rates in HCV GT3 Patients
- 30. * Patients with BL RAS testing results; NS5A RASs not available in n = 22 patients
- 31. PS-159, Wedemeyer: Safety and Efficacy of the Fixed-dose Combination Regimen of Uprifosbuvir (MK-3682)/Grazoprevir/Ruzasvir in Cirrhotic or
- 32. THU-264, Serfaty: High SVR24 Rates in Participants with Chronic HCV GT1, 2, 3 Infection Following 16
- 33. FRI-233, Chhatwal: Projection of Patients Who Fail Treatment in the Era of Direct-Acting Antivirals Modelling Natural
- 34. Patients with Chronic Kidney Disease
- 35. Executive Summary G/P demonstrates high SVR12 and favorable safety across all genotypes and all CKD stages
- 36. SAT-273, Pol: Safety and Efficacy of G/P in Adults with Chronic HCV Infection GT1–6 as a
- 37. FRI-219, Nazario: Full Dose, Daily SOF Treatment in End-Stage Renal Disease: Tolerability and Safety of Largest
- 38. FRI-229, Kuo: No Adverse Renal Side Effects in Patients with Mild to Moderate Renal Dysfunction Treated
- 39. THU-269, Theocharidou: Changes in Renal Function in Patients with Hepatitis C-Related Cirrhosis Treated with DAA Agents
- 40. SAT-297, Younossi: EBR/GZR Effectiveness in Patients with Chronic HCV and Chronic Kidney Disease: Real-World Experience from
- 41. Other Populations
- 42. Executive Summary Summary: It appears to be a question as to whether special patient populations still
- 43. LBP-522, Rockstroh: Efficacy and Safety of G/P in Patients Co-infected with Hepatitis C and Human Immunodeficiency
- 44. LBO-03, Reau: MAGELLAN-2: Safety and Efficacy of G/P in Liver or Renal Transplant Adults with Chronic
- 45. PS-130, Litwin: PREVAIL: Intensive Models of HCV Care for People Who Inject Drugs OAT = Outcomes,
- 46. FRI-234, Grebely; The SIMPLIFY Study: Efficacy and Safety of SOF/VEL in People with Chronic HCV Infection
- 47. DDIs and PK
- 48. Executive Summary Data presented at EASL allowed for a better understanding of the comparison of DDIs
- 49. FRI-187, Garrison: Drug-Drug Interaction Profile of SOF/VEL/VOX Fixed-Dose Combination ARVs, antiretrovirals; ATV, atazanavir; EFV, efavirenz; FTC,
- 50. Real World Evidence
- 51. Executive Summary RWE continues to confirm the results of clinical trials across the currently approved regimens
- 52. SAT-244, Tsai: Utilization of DAA therapies LDV/SOF and SOF/VEL in Patients with GT1 HCV: Real-world experience
- 53. SAT-222, Khalili: Safety and Efficacy of SOF/VEL ± RBV for the Treatment of HCV GT1–6: Results
- 54. PS-102, Curry: Utilization of SOF/VEL in GT2–6 HCV: Real-World Experience from the TRIO Network PP, per-protocol
- 55. FRI-247, Vermehren: Use of the 6 Million Viral Load Cut-off to Guide Treatment Duration with LDV/SOF
- 56. FRI-239, McCombs: Analysis of the Real-World Treatment Effectiveness of EBR/GZR HCC, hepatocellular carcinoma; TE, treatment-experienced; TN,
- 57. THU-237, Pearlman: Safety and Efficacy of EBR/GZR ± RBV for the Treatment of HCV GT1: Results
- 58. SAT-297, Younossi: EBR/GZR Effectiveness in Patients with Chronic HCV and Chronic Kidney Disease: Real-World Experience from
- 59. THU-239, Bacon: Real-World Use of EBR/GZR and Outcomes in Patients with Chronic Hepatitis C: Retrospective Data
- 60. Sat-279, Flamm: Real-World Treatment Utilisation and Results in the Renaissance of HCV Care: Analyses of Treatment
- 61. THU-284, Maunoury: Cost-Effectiveness of EBR/GZR Regimen for Treating HCV GT1 Infection in Stage 4–5 Chronic Kidney
- 62. PS-096, Deterding: Long-Term Follow-Up After IFN-Free Therapy of Advanced HCV-Associated Liver Cirrhosis: Continued Improvement of Liver
- 63. SAT-229, Sulkowski: Incidence of and Predictors for DAA Treatment Failure Among 4099 HCV GT1 Infected Adults:
- 64. FRI-280, Kondili: Clinical Characterization and Economic Impact Evaluation of Anti-HCV DAA Treatment Failure: Real-Life Data From
- 65. PS-097, Freeman: 94% SVR with Parallel Imported Generic DAA Treatment for HCV * GT2 results almost
- 66. New Molecules
- 67. PS-153, Gane: Short duration treatment with AL-335 and odalasvir (ODV) ± SMV, in treatment naive patients
- 68. OBV/PTV/r + DSV
- 69. Executive Summary Real world results confirm safety and effectiveness of 2D and 3D – including patients
- 70. SAT-226, Londoño: Effectiveness, Safety/Tolerability of OBV/PTV/r ± DSV in Patients with HCV GT1 or 4 with/without
- 71. FRI-267, Agarwal: CORAL-I (Cohorts 3–6): Safety and Efficacy of OBV/PTV/R ± DSV ± RBV in Adult
- 72. THU-251, Leung: ZIRCON: Pharmacokinetics, Safety, and Efficacy of OBV/PTV/r ± DSV ± RBV in Adolescents with
- 73. FRI-269, Buggisch: Effectiveness, Safety and Quality of Life in Patients Treated with OBV/PTV/r ± DSV ±
- 74. FRI-250, Lubel: Very High Real-World Efficacy of OBV/PTV/r + DSV ± RBV in HCV GT1 in
- 75. THU-277, Sanai: 100% Efficacy to OBV/PTV/r ± DSV ± RBV in HCV GT1 and 4-Infected Hemodialysis
- 76. SAT-239, Alkadi: Decline in eGFR in HCV-Infected Patients While on Treatment with LDV/SOF or OBV/PTV/r +
- 77. Extrahepatic Manifestations
- 78. Executive Summary Accumulating evidence for cyroglobulinemia, cardiovascular events and infertility/pregnancy outcomes provide additional argument for initiating
- 79. SAT-216, Sanchez-Gonzalez: The Cumulative Prevalence and Incidence of Extra-Hepatic Manifestations in Patients with HCV Infection: Real-World
- 80. PS-099, Saadoun: VASCUVALDIC 2 study: SOF + DCV for HCV-cryoglobulinemia vasculitis (HCV-CryoVas) Open label study of
- 81. PS-099, Saadoun: VASCUVALDIC 2 study: SOF + DCV for HCV-cryoglobulinemia vasculitis (HCV-CryoVas) Open label study of
- 82. PS-032, Cacoub: The Cumulative Prevalence and Incidence of Extra-Hepatic Manifestations in Patients with HCV Infection: RWE
- 83. SAT-217, Villa: Extra-hepatic manifestations from hepatitis C virus infection related to female infertility and adverse pregnancy
- 84. HEOR
- 85. Executive Summary Screening younger age cohorts will increase overall costs but is cost-effective relative to the
- 86. FRI-183, Barocas: Population Level Outcomes and Cost-Effectiveness of Expanding Guidance for Age-Based Hepatitis C Testing in
- 87. FRI-458, Rein: The Cost-Effectiveness of a One Time HCV Antibody Test Followed by Treatment for All
- 88. SAT-225, Buti: Cost-Effectiveness of Screening for HCV in Population Born Between 1956 and 1970 in Spain
- 89. Diagnosis and Linkage to Care
- 90. Executive Summary There remains significant challenges in terms of screening, diagnosis, and connection to care Alternative
- 91. FRI-478, Udompap: An Alternative Screening Strategy for HCV Infection Among Americans Not Belonging in the Baby
- 92. THU-189, Pratt: An Audit of Hepatitis C Screening and Referral Patterns to a Specialist Hepatology Service
- 93. SAT-194, Wong: Low Rates of HCV Testing and HCV Awareness Among Individuals at High Risk for
- 94. FRI-475, Scott: Reaching HCV Elimination Targets Requires Health System Interventions to Enhance the Care Cascade OST,
- 95. HBV Reactivation
- 96. Executive Summary Data on HBV reactivation after HCV DAA therapy are unlikely to be clinically relevant
- 97. Liu, PS-098: 12 Weeks LDV/SOF is Safe and Effective in Patients with Chronic HCV/HBV Coinfection: A
- 98. THU-144, Tang: Absence of Hepatitis B Reactivation Among Veterans with Serological Evidence of Previous Hepatitis B
- 100. Скачать презентацию
Congress Overview
EASL 2017 data provides further evidence for the emerging treatment
Congress Overview
EASL 2017 data provides further evidence for the emerging treatment
G/P: integrated analyses have demonstrated high efficacy across different patient types, regardless of baseline patient or viral characteristics
LDV/SOF: RWE data continues to support the potential expanded use in GT1 patients irrespective of HCV RNA baseline viral load
SOF/VEL/VOX: integrated analyses have identified multiple baseline predictors associated with lower SVR rates in GT1a patients
From the data presented at EASL 2017, two regimens are expected to dominate the retreatment landscape: 16 weeks of G/P (MAGELLAN-1 Part 2) and 12 weeks of SOF/VEL/VOX (POLARIS integrated analyses)
EASL 2017 saw the release of data for many patient groups considered once difficult to treat, including patients with CKD, PWID, HIV/HCV coinfection and post-liver/renal transplant; these data bring into question whether special patient populations still exist with highly efficacious next-generation DAAs
EASL 2017 saw the release of a wealth of RWE data, including first reports of the use of SOF/VEL and EBR/GZR I real-life clinical practice; RWE continues to confirm the results of clinical trials across the currently approved regimens (OBV/PTV/r + DSV, LDV/SOF, SOF/VEL, EBR/GZR)
TN NC, treatment-naive, non-cirrhotic; RWE, real-world evidence; CKD, chronic kidney disease; PWID, persons who inject drugs.
Outline: EASL 2017 Highlights
Outline: EASL 2017 Highlights
DAA-Naive ± Cirrhosis
DAA-Naive ± Cirrhosis
Executive Summary
Emerging treatment paradigm to establish 8 weeks of treatment for
Executive Summary
Emerging treatment paradigm to establish 8 weeks of treatment for
G/P demonstrates consistently high efficacy across different patient types regardless of baseline patient or viral characteristics
Limited RW data suggests that LDV/SOF use for GT1 patients may be expanded based on RWE data suggesting a HCV RNA baseline viral load >6 million IU/mL has no impact on SVR
Multiple baseline predictors were associated with lower SVR rates in GT1a patients treated for 8 weeks with SOF/VEL/VOX
Studies continue to pursue mix and match regimens (DCV + SOF, EBR/GZR + SOF) for 8 weeks in TN NC patients; this could be a feasible option for select markets
GS-007, Foster: ENDURANCE-3: Safety and Efficacy of G/P Compared to
SOF
GS-007, Foster: ENDURANCE-3: Safety and Efficacy of G/P Compared to SOF
BT, breakthrough; d/c, discontinuation; IDU, injection drug use; ND, not determined; non-VF, non-virologic failure; RAS, resistance-associated substitution.
* NS3 sequences not determined; † One patient with VF had poor adherence and both NS3 + NS5A baseline RASs.
Treatment-naive, GT3-infected patients without cirrhosis were randomized 2:1 to receive 12 weeks of either G/P or SOF + DCV, or were assigned to an 8-week G/P arm
149
157
111
115
222
233
12 weeks
12 weeks
8 weeks
1 BT
3 relapse
7 non-VF
0 BT
1 relapse
3 non-VF
1 BT
5 relapse
2 non-VF
Non-inferior to
12-week SOF + DCV
Non-inferior to
12-week G/P
n
N
SAT-233, Puoti: High SVR Rates with 8 and 12 Weeks of
SAT-233, Puoti: High SVR Rates with 8 and 12 Weeks of
mITT, excludes patients with non-virologic failure.
* All GT3 patients were treatment-naive;
† GT1: n = 1; GT3: n = 1; ‡ GT3: n = 1; § GT2: n = 2; GT3: n = 5; ║ GT3: n = 3;
¶ N adjusted for patients with missing data and excludes non-virologic failure.
Integrated efficacy analysis of 8 or 12 weeks’ G/P treatment in non-cirrhotic patients with
GT1–6 infection across seven phase 2 or 3 clinical trials
Logistic regression analysis showed presence of baseline NS3 155, 156, or 168 RASs combined with NS5A RASs had a statistically significant impact on SVR12 (P<0.0001) in this analysis
<1% of patients had the combination of RASs and
most achieved SVR12 (78%; 7/9)
SAT-233, Puoti: High SVR Rates with 8 and 12 Weeks of
SAT-233, Puoti: High SVR Rates with 8 and 12 Weeks of
TE, treatment-experienced; Tx, treatment compliant; OST, opioid substitute therapy.
Integrated efficacy analysis of 8 or 12 weeks’ G/P treatment in non-cirrhotic patients with
GT1–6 infection across seven phase 2 or 3 clinical trials
409
416
571
575
87
87
155
155
150
152
178
178
40
40
65
65
168
171
274
274
15
15
18
18
197
201
219
221
665
668
856
859
54
56
86
87
85
89
117
117
135
138
189
192
59
59
123
123
61
61
58
59
87
88
91
91
FRI-238, Dufour: Safety of G/P in Adults with Chronic GT1–6 HCV
FRI-238, Dufour: Safety of G/P in Adults with Chronic GT1–6 HCV
d/c, discontinuation; GGT, gamma-glutamyl transferase; PI, protease inhibitor; PRS, pegIFN/RBV or SOF + RBV ± pegIFN.
* NS5A- and/or PI experienced; † Of the total eight patients, three experienced a total of nine DAA-related AEs leading to study drug d/c,
including abdominal pain, diarrhoea, dyspepsia, nausea, fatigue, malaise, dizziness, headache, and transient ischaemic attack;
‡ Four (0.2%) patients experienced any DAA related AE with ≥ grade 3, including upper abdominal pain, asthenia, migraine, and increased ALT, AST, and GGT;
§ Causes of death were pneumonia, accidental overdose, adenocarcinoma, hepatic cancer metastatic, cerebral haemorrhage,
alcohol poisoning and toxicity to various agents (none were considered to be related to treatment); ¶ Increased grade from baseline result;
# One patient experienced grade 3 and above ALT (>5 × ULN) elevations concomitant with total bilirubin (>2 × ULN) elevations
1 day post-treatment. Lab abnormalities were consistent with an obstructive pattern, most likely due to transient passage of a biliary stone;
$ Most elevations were predominantly indirect bilirubin without associated ALT increase in patients with indirect Gilbert’s syndrome.
Patients received G/P for 8 weeks (non-cirrhotic; n = 828), 12 weeks (n = 1317; 225 [17%] with compensated cirrhosis) or 16 weeks (n = 120; 63 [53%] with compensated cirrhosis)
The frequency and severity of AEs were similar between non-cirrhotic patients and cirrhotic patients
GS-006, Forns: EXPEDITION-I: Efficacy and Safety of G/P for Treatment of
GS-006, Forns: EXPEDITION-I: Efficacy and Safety of G/P for Treatment of
d/c, discontinuation; PTW, post-treatment Week; RAS, resistance-associated substitution.
* SOF + RBV ± pegIFN.
Patient with history of hemophilia died due to cerebral hemorrhage (not related to study drug)
Baseline RAS prevalence
NS3, 2/133 (2%); NS5A, 53/133 (40%); NS3 + NS5A, 2/133 (2%)
THU-263, Gane: Pharmacokinetics and Safety of G/P in Adults with chronic
THU-263, Gane: Pharmacokinetics and Safety of G/P in Adults with chronic
CC, compensated cirrhosis; CP, Child-Pugh; DILI, drug-induced liver injury; d/c, discontinuation; RI, renal impairment; PK, pharmacokinetics.
* Baseline fibrosis stage was defined for subjects with non-missing liver biopsy scores, FibroScan scores, or FibroTest scores; cirrhosis status was
determined as collected in EDC; † 1 patient had a CP score of 7; ‡ Both deaths due to AE (cerebral hemorrhage) and not deemed related to treatment.
An integrated safety and PK analysis of HCV GT1–6-infected patients with compensated cirrhosis treated with G/P for 12 or 16 weeks from four phase 2 and 3 clinical trials (EXPEDITION-1 and 4, SURVEYOR-II, and MAGELLAN-1)
Patients received G/P for 12 weeks (n = 245, including 20 patients with severe renal impairment
[baseline eGFR of < 30 mL/min/1.73 m2]) or 16 weeks (n = 63)
Patient with a history of esophageal varices experienced an AE (esophageal variceal bleeding) with a sign of hepatic decompensation; event was not deemed related to study drug
There were no grade 3 ALT increases and no cases consistent with DILI
GLE exposures in patients with compensated cirrhosis were
2.2-fold higher than in non-cirrhotics; PIB exposures were similar
FRI-205, Krishnan: Pooled Resistance Analysis in HCV GT1–6-Infected Patients Treated with
FRI-205, Krishnan: Pooled Resistance Analysis in HCV GT1–6-Infected Patients Treated with
RAS, resistance-associated substitution; TE, treatment-experienced; VF, virologic failure.
* Using next-generation sequencing (2% and 15% thresholds);
† Includes polymorphisms at amino acid positions 155, 156, 168 in NS3, and 24, 28, 30,
31, 58, 92, 93 in NS5A relative to the subtype specific reference sequence:
‡ A30x is A30L/M/R/S/T/V.
A pooled resistance analysis* was conducted in HCV GT1–6-infected patients with or without compensated cirrhosis (N = 2256) treated with G/P for 8, 12, or 16 weeks from eight
phase 2 and 3 clinical trials
High incidence of baseline NS5A RASs in GT2, GT4 and GT6 was driven by detection of:
L/M31 (in GT2a and GT2b) and R30K (GT2c)
position 58 (GT4a, 4d, and 4f)
position 28 (GT6)
NS3
NS5A
‡
Baseline NS3 RASs did not impact SVR12 rates in
GT3 patients
Baseline NS5A A30K and Y93H had minimal impact on efficacy, except in TE patients treated 12 weeks
There were 22 virologic failures (1%)
(GT1a [n = 2], GT2a [n = 2], GT3a [n = 17], GT3b [n = 1])
Baseline RASs did not impact SVR in GT1 and GT2 patients and there were no virologic failures in GT4–6 patients
Baseline polymorphisms in GT3 patients
FRI-262, Chayama: CERTAIN-1: Efficacy and Safety of G/P in Japanese Patients
FRI-262, Chayama: CERTAIN-1: Efficacy and Safety of G/P in Japanese Patients
BL, baseline; C, cirrhosis; d/c, discontinuation; ITT, intent-to-treat;
ITT-PS, ITT population excluding patients with the HCV Y93H polymorphism; LTFU, lost to follow-up; NC, no cirrhosis. * 15% cut off.
Phase 3 study evaluating the safety and efficacy of G/P for 8 or 12 weeks or OBV/PTV/r for
12 weeks in Japanese patients with HCV GT1-infection without cirrhosis (Arms A and B) or with compensated cirrhosis (Arm C)
Among non-cirrhotic patients treated with G/P for 8 wks, all patients with BL Y93H RAS (n = 23) achieved SVR
FRI-263, Chayama: Efficacy and Safety of G/P in Japanese Patients with
FRI-263, Chayama: Efficacy and Safety of G/P in Japanese Patients with
C, cirrhosis; d/c, discontinuation; LTFU, lost to follow-up;
mITT, excludes non-virologic failures; NC, no cirrhosis; RL, relapse.
* Nausea and vomiting; † Malaise; ‡ Drug eruption, characterised as purpuric rash and eczema.
Phase 3 study of the safety and efficacy of G/P for 8 (CERTAIN-2) or 12 (CERTAIN-1) weeks in Japanese patients with HCV GT2-infection without cirrhosis (Arms A and B) or with compensated cirrhosis (Arm C)
DAA-related AEs were significantly different between Arm A and Arm B (P<0.001)
8 weeks G/P achieved
non-inferiority compared with 12 weeks
SOF + RBV
1 LTFU
1 d/c
2 RL
1 d/c
THU-273, Lawitz: Treatment with SOF/VEL or SOF/VEL/VOX is Well Tolerated and
THU-273, Lawitz: Treatment with SOF/VEL or SOF/VEL/VOX is Well Tolerated and
* HCV RNA < 6 million IU/mL.
GT1
GT1a
GT1b
GT2
GT3
GT4
GT5
GT6
F0–2
F3
F4
LDV/SOF
all patients SVR12: GT1 95% (35/37), GT1a 94% (30/32), GT1b 100% (5/5)
85
87
LDV/SOF
all patients SVR12: GT1 90% (35/39), GT1a 86% (25/29), GT1b 100% (9/9)
14
14
19
19
63
65
11
11
10
10
22
22
3
3
8
8
303
303
202
202
100
100
195
195
218
221
101
101
23
23
31
31
127
133
85
90
42
43
41
43
90
90
40
41
13
14
23
23
91
92
66
66
25
26
34
34
76
76
20
21
5
5
6
6
31
33
21
23
9
9
5
5
22
22
5
6
1
1
4
4
152
155
105
107
47
48
58
58
154
163
49
49
5
5
13
13
55
63
45
52
10
11
15
15
85
87
11
11
2
2
3
3
Trials analysed: ION-3; ASTRAL-1, -2, and -3; POLARIS-2 and -3; POLARIS-2 and -3
Data presented is the completer population: All patients who completed treatment, and had HCV RNA data at post-treatment week 12 or a later time point
SAT-280, Roberts: SOF/VEL/VOX Results in High SVR12 Rates When Administered for
SAT-280, Roberts: SOF/VEL/VOX Results in High SVR12 Rates When Administered for
BT, breakthrough; DAA-E, direct-acting antiviral treatment-experienced; DAA-N, direct-acting antiviral treatment-naïve; OT, other; RL, relapse.
Retrospective analysis of HCV GT1–6 infected patients treated with SOF/VEL/VOX for 8 weeks (DAA-naive) or 12 weeks (DAA-experienced) in the phase 3 POLARIS studies
59
63
1 BT
2 RL
3 OT
1 OT
4 RL
2 OT
1 RL
1 OT
14 RL
2 RL
2 RL
2 RL
3 OT
2 RL
2 OT
1 RL
SVR12
rates were generally lower across subgroups in GT1a patients
SVR12 was lower in
DAA-naive GT1a patients
THU-257, Wyles: No Impact of RASs on the High Efficacy of
THU-257, Wyles: No Impact of RASs on the High Efficacy of
BL, baseline; NS3 and NS5A RASs, substitutions that confer >2.5 fold reduced susceptibility to any NS3 or NS5A inhibitor; RASs, resistance associated substitutions;
TE, treatment emergent. * 15% cut-off.
SVR12 was 98% (41/42) in
patients with BL NS5B RASs
Integrated resistance analysis of baseline* and treatment emergent NS3, NS5A and NS5B RASs in DAA-naive HCV GT1-6 patients treated with SOF/VEL/VOX for 8 weeks in the phase 3 POLARIS-2 and -3 studies (RASs detected at 15% cut-off)
n
N
106
110
94
103
23
26
27
27
1
1
33
35
149
151
5
5
32
32
22
23
21
22
65
66
NS3
NS5A
80 any
155 any
156 any
168 any
28 any
30 any
31 any
93 any
66
74
1
1
16
17
0
0
41
41
28
30
39
42
27
27
SVR12 was 100% (24/24) in GT3 patients with BL Y93H RAS
SVR12 was 88% (51/58) in GT1a patients with BL NS3 Q80K RAS
SAT-236, Manns: The Safety and Tolerability of SOF/VEL/VOX for 8 or
SAT-236, Manns: The Safety and Tolerability of SOF/VEL/VOX for 8 or
D/C, discontinuation; PTD, post-treatment Day; SAEs; serious adverse event. * Assessed as unrelated to treatment.
Retrospective safety analysis of 1056 HCV GT1–6 infected DAA-experienced (POLARIS-1 and -4) or DAA-naive (POLARIS-2 and -3) patients with or without compensated cirrhosis
POLARIS-1: SOF/VEL/VOX vs placebo (12 weeks)
POLARIS-4: SOF/VEL/VOX vs SOF/VEL (12 weeks)
POLARIS-2 and -3: SOF/VEL/VOX (8 weeks)
vs SOF/VEL (12 weeks)
DAA-naive
DAA-experienced
Most cases of diarrhea and nausea in the SOF/VEL/VOX group were grade 1;
no grade 3/4 events
Older age, Asian race, cirrhosis and mild renal impairment did not impact incidence or severity of AEs in the SOF/VEL/VOX group
1 patient in the SOF/VEL/VOX group had a grade 3 elevation of ALT, while 1 patient had a grade 3 bilirubin elevation
FRI-213, Foster: EBR/GZR + SOF ± RBV in Treatment-Naive and Treatment-Experienced
FRI-213, Foster: EBR/GZR + SOF ± RBV in Treatment-Naive and Treatment-Experienced
BL, Baseline; DC/AE, discontinuation due to AE; FAS, Full set analysis; LTFU, lost to follow-up; RAS, resistance-associated substitution; RL, relapse;
VF, virologic failure; WC, withdrew consent.
*1 patient has Y93H, P58S & S62T RASs present at BL and P58S & S62T present at treatment-failure; 1 patient has no RAS present; † Y93H RAS was not present at
treatment failure in patient who did not achieve SVR; ‡ 1 case of each (lung infection, creatinine increased, chest pain, opiate overdose, and cellulitis);
§ 1 patient had a drug-related SAE of vomiting on Day 4 and subsequently d/c treatment on Day 7 due to cellulitis; || Lowest level was 8.9 g/dL.
52% (50/97) of patients had baseline NS5A RASs; 9 patients had Y93H RASs (1% level of detection)
C-ISLE: UK study of patients with HCV GT3 infection and compensated cirrhosis
treated with EBR/GZR + SOF ± RBV for 8–16 weeks (N = 100)
2 RL*
n
N
21
23
21
24
16
17
17
18
15
18
3 LTFU/WC
1 LTFU/WC
2 LTFU/WC
1 DC/AE
Treatment-naive
pegIFN/RBV treatment-experienced
Baseline NS5A RASs
98% SVR12 (49/50) in patients
with baseline NS5A RASs
98% SVR12 (46/47) in patients
without baseline NS5A RASs
89% SVR12 (8/9) in patients with Y93H RAS at BL†
Randomized 1:1 (n=47)
Randomized 1:1:1 (n=53)
1 LTFU/WC
29% Asian
47% treatment-naive
FAS population
THU-249, Hezode: Efficacy and Safety of SOF and DCV for 8
THU-249, Hezode: Efficacy and Safety of SOF and DCV for 8
BL, baseline; FS, FibroScan Score; TE, treatment-emergent.
* A30V (n = 1); S62L/Y93H (n = 1).
Ongoing, multicenter, open-label, single-arm pilot study evaluating the safety
and efficacy of DCV + SOF for 8 weeks in treatment-naive patients with
HCV GT3 infection without cirrhosis
4 relapses
No safety signal reported
Resistance analysis
BL S62L/Y93H NS5A RAS (n = 1); TE A30K/Y93H
(n = 1); poor compliance (n = 1); data not available (n = 1)
THU-258, Troland: 12 Weeks of SOF, DCV and RBV for GT3
THU-258, Troland: 12 Weeks of SOF, DCV and RBV for GT3
CP, Child Pugh; D/C, discontinuation; IQR, interquartile range; LSM, liver stiffness measurement; TE, treatment-experienced; TN, treatment-naive.
* LSM data available for 43 patients; † CP A vs CP B/C; ‡ IFN/RBV-experienced; § IFN/RBV/SOF-experienced.
Real-world study of DCV + SOF + RBV for 12 weeks in
HCV GT3-infected patients with cirrhosis in Scotland
Quantifiable RNA at Week 4 was associated with numerically lower SVR12 vs unquantifiable RNA at Week 4 (75% [12/16] vs. 94% [33/35]; p=0.069)
SVR12 rates were similar to those in clinical trials
p = 0.76†
No D/C due to drug-related AEs
4
5
3
4
‡
§
DAA-Experienced
DAA-Experienced
Executive Summary
Patients who have failed a DAA-containing regimen are a minority
Executive Summary
Patients who have failed a DAA-containing regimen are a minority
The data reported for G/P established the 16 week regimen as a efficacious and safe retreatment option for the majority of GT1 DAA failures in 2018 and beyond
16 weeks of G/P in GT1 NS5A failures resulted in a 94% SVR12 rate
17/19 LDV/SOF failures achieved SVR12. LDV/SOF failures will represent the majority of DAA failures in the near future
12 weeks of G/P in GT1 NS3 failures resulted in a 100% SVR12 rate
Additional analyses reported for 12 weeks of SOF/VEL/VOX further support its use in the DAA failure population across all genotypes
The efficacy was ≥95% SVR12 irrespective of baseline characteristics
Two regimens are expected to dominate the retreatment landscape: 16 weeks of G/P and 12 weeks of SOF/VEL/VOX
G/P has a longer treatment duration, is restricted to GT1 but appears to have a cleaner safety profile
PS-156, Poordad: MAGELLAN-1, PART 2: G/P for 12 or 16 Weeks
PS-156, Poordad: MAGELLAN-1, PART 2: G/P for 12 or 16 Weeks
BT, breakthrough; d/c, discontinuation; PI, protease inhibitor.
Randomized trial of G/P for 12 or 16 weeks in HCV GT1- or GT4-infected patients with prior DAA failure, without cirrhosis or with compensated cirrhosis
39
44
43
47
Treatment duration
1 BT
4 relapse
4 BT
SVR12 rate by prior DAA therapy
14
14
14
16
11
14
13
13
17
18
13
16
n
N
n
N
N = 19 patients had previously failed LDV/SOF
N = 10 had previously failed ≥2 DAA-containing regimens
SAT-204, Pilot-Matias: Resistance Analysis in the MAGELLAN-1 Study (Part 2): G/P
SAT-204, Pilot-Matias: Resistance Analysis in the MAGELLAN-1 Study (Part 2): G/P
NGS, next-generation sequencing; OTVF, on-treatment virologic failure; PI, protease inhibitor; RAS, resistance-associated substitution; wks, weeks.
NGS (detection threshold of 15%) was used to perform resistance analysis of HCV from
DAA-experienced patients treated with 12- or 16-week G/P from the MAGELLAN-1 (Part 2) study
13
13
2
2
20
24
4
5
13
13
4
4
22
23
1
4
SVR12 rate by baseline RASs
1 OTVF
3 relapse
1 relapse
1 OTVF
3 OTVF
PI + NS5A-
experienced
(N = 30)
SVR12 % (n/N)
NS5A-
experienced,
PI-naive
(N = 32)
PI-experienced,
NS5A-naive
(N = 26)
None
NS3 only
NS5A only
(single)
NS5A only
(multiple)
NS3 + NS5A
Prevalence (%)
n
N
THU-305, Ng: Resistance Selection Using GLE and PIB in Replicons of
THU-305, Ng: Resistance Selection Using GLE and PIB in Replicons of
* Relative to GLE EC50s for the respective wild-type replicons in transient transfection assays: GT1a: 0.21 nM; GT1b: 0.47 nM; GT2a: 2.5 nM; GT2b: 3.1 nM;
GT3a: 0.55 nM; GT4a: 0.67 nM; GT4d: 0.15 nM; GT6a: 0.15 nM; † Relative to GLE EC50s for the respective wild-type replicons in transient transfection assays:
GT1a: 0.72 pM; GT1b: 1.9 pM; GT2a: 0.99 pM; GT2b: 1.2 pM; GT3a: 0.65 pM; GT4a: 0.78 pM; GT5a: 0.93 pM; GT6a: 1.0 pM.
The in vitro resistance profiles of GLE or PIB in major HCV genotypes were determined
using drug-resistant replicon colony selection
Activity of GLE against common GT1–4 and 6 RASs
Activity of PIB against common GT1–6 RASs
GLE predominantly selected NS3 A156 substitutions in GTs 1–4 and D168 substitutions in GT6 in vitro
PIB selected few NS5A substitutions in vitro
SAT-280, Roberts: SOF/VEL/VOX Results in High SVR12 Rates When Administered for
SAT-280, Roberts: SOF/VEL/VOX Results in High SVR12 Rates When Administered for
BT, breakthrough; DAA-E, direct-acting antiviral treatment-experienced; DAA-N, direct-acting antiviral treatment-naïve; OT, other; RL, relapse.
Retrospective analysis of HCV GT1–6 infected patients treated with SOF/VEL/VOX for 8 weeks (DAA-naive) or 12 weeks (DAA-experienced) in the phase 3 POLARIS studies
59
63
1 BT
2 RL
3 OT
1 OT
4 RL
2 OT
1 RL
1 OT
14 RL
2 RL
2 RL
2 RL
3 OT
2 RL
2 OT
1 RL
THU-248, Sarrazin: No Impact of RASs on the High Efficacy of
THU-248, Sarrazin: No Impact of RASs on the High Efficacy of
RASs, resistance associated substitutions * 15% cut-off; † VOX- or VEL-specific RASs that confer >2.5-fold change compared with GT-specific reference.
Integrated resistance analysis of baseline* and treatment-emergent NS3, NS5A and NS5B RASs in DAA-experienced HCV GT1–6 patients treated with SOF/VEL/VOX for 12 weeks in the phase 3 POLARIS-1 (NS5A inhibitor-experienced) and -4 (DAA-experienced) studies
GT3-infected patients:
93% (25/27) with Y93H NS5A RAS achieved SVR12
Of the 7 patients who relapsed (POLARIS-1, n = 6; POLARIS-4, n = 1), 1 (GT4d) had treatment-emergent NS5A Y93H RAS
VOX- or VEL-specific RASs did not impact SVR12
97% (32/33) of patients with NS5B RASs achieved SVR12
†
* Patients with BL RAS testing results.
PS-155, Vermehren; High SVR Rates
* Patients with BL RAS testing results.
PS-155, Vermehren; High SVR Rates
SOF + RBV failures*
N = 73
SOF + RBV Failures
n = 86
Resistance Analysis after SOF + RBV failure
SOF/VEL + RBV (n=1)
DCV + SOF ± RBV (n=9)
DCV + SOF ± RBV (n=14)
LDV/SOF + RBV (n=1)
SOF/VEL ± RBV (n=15)
Week 0
12
24
FU12
Retreatment with an NS5A-inhibitor (n=40)
Interim analysis: SVR 88% (n=21/24)
1 patient with VEL failure did not take RBV
Real-world data from treatment-experienced patients with HCV GT3 infection treated with DCV + SOF ± RBV for 12–24 weeks or SOF ± VEL/LDV ± RBV for 12–24 weeks
1
* Patients with BL RAS testing results; NS5A RASs not available
* Patients with BL RAS testing results; NS5A RASs not available
PS-155, Vermehren; High SVR Rates in HCV GT3 Patients ± Cirrhosis Treated
with DCV + SOF or SOF/VEL ± Ribavirin According to Baseline Resistance Analysis
DCV + SOF ± RBV failures*
N = 73
DCV + SOF ± RBV Failures
n = 80
Resistance Analysis after DCV + SOF ± RBV failure
Real-world data from treatment-experienced patients with HCV GT3 infection treated with DCV + SOF ± RBV for 12–24 weeks or SOF ± VEL/LDV ± RBV for 12–24 weeks
2
Retreatment of GT3 patients who failed a first course of DCV + SOF therapy
1 patient with VEL failure did not take RBV
PS-159, Wedemeyer: Safety and Efficacy of the Fixed-dose Combination Regimen of
PS-159, Wedemeyer: Safety and Efficacy of the Fixed-dose Combination Regimen of
BL, baseline.
*1 patient withdrew from the study after taking 3 doses of study drug; † One participant in 24 week arm had unknown cirrhosis status
‡ RASs detected by next-generation sequencing with 15% sensitivity NS5A RAS = any change from wild-type at position 28, 30, 31 or 93;
NS3 RASs = any change from wild-type at positions 36, 54, 55, 56, 80, 107, 122, 132, 155, 156, 158, 168, 170 or 175);;
A multicentre, open-label, randomized (1:1) study in n = 94 HCV GT1-infected patients who relapsed after receiving LDV/SOF or EBR/GZR
No DAA-related SAEs or d/c due to AEs
BL NS5A or NS3 RASs† had no impact on SVR12 and all patients with BL NS5A Y93 RAS achieved SVR
THU-264, Serfaty: High SVR24 Rates in Participants with Chronic HCV GT1,
THU-264, Serfaty: High SVR24 Rates in Participants with Chronic HCV GT1,
* One GT2 withdrew after single dose with SAEs of vomiting and tachycardia; † >5-fold reduction in susceptibility to RZR in vitro.
83% (19/23) had RASs in both NS3 and NS5A
High-impact RASs† were detected in:
77% (10/13) GT2 (L31M, F28C)
88% (7/8) GT3 (Y93H, A30K, L31M, S62L)
8
8
1 d/c*
Retreatment with GZR + RZR + UPR + RBV for 16 weeks in HCV GT1, 2, 3 non-cirrhotic patients that experienced relapse following 8 weeks of a 3-DAA regimen in Part A of C-CREST
FRI-233, Chhatwal: Projection of Patients Who Fail Treatment in the Era
FRI-233, Chhatwal: Projection of Patients Who Fail Treatment in the Era
Modelling
Natural history and disease progression were modelled using published meta-analyses and observational models
DAA treatment was modelled in different waves:
TVR, BOC launched in 2011
SOF/SMV, SOF+RBV±IFN in 2014
Multiple NS5A-inhibitors from 2015
F3–F4 patients assigned priority
SVR rates taken from published EU/US RW data
Non-cirrhotic NS5A treatment failures were not re-treated until 2018, after which they were eligible for re-treatment with new NS5As
Majority of treatment failures will occur in patients treated with NS5A inhibitors, or who are cirrhotic, or infected with HCV GT1a
Patients with Chronic Kidney Disease
Patients with Chronic Kidney Disease
Executive Summary
G/P demonstrates high SVR12 and favorable safety across all genotypes
Executive Summary
G/P demonstrates high SVR12 and favorable safety across all genotypes
Only option for GT2–3 patients with severe CKD, including those on hemodialysis
Real world data are emerging for the use of SOF-based regimens in patients with severe CKD with attempts to establish safety and effectiveness
Conflicting data presented on impact of SOF on eGFR
First real-world data confirmed the effectiveness of EBR/GZR in patients across all stages of CKD
One analysis demonstrated the difficulty in capturing true renal function changes; no correlation was found between MDRD, cystatin-C and NGAL biomarkers with traditional biomarkers eGFR or Creatinine
SAT-273, Pol: Safety and Efficacy of G/P in Adults with Chronic
SAT-273, Pol: Safety and Efficacy of G/P in Adults with Chronic
CKD, chronic kidney disease; d/c, discontinuation; ITT, intent-to-treat; PK, pharmacokinetic.
* DAA-related SAE was transient ischemic attack (patient d/c treatment and did not achieve SVR12); †Causes of death (all not related to study drug):
CKD stage 1 (n=3) pneumonia, accidental overdose, alcohol poisoning and toxicity to various agents; CKD stage 2 (n=1) cerebral haemorrhage;
CKD stage 3 (n=1) adenocarcinoma; CKD stage 4–5 (n=1) cerebral haemorrhage.
An integrated efficacy, safety, and PK analysis of HCV GT1–6-infected patients treated with G/P for
8 (n = 822), 12 (n = 1347), or 16 (n = 69) weeks from eight phase 2 and 3 clinical trials, as a function of CKD stage
Patients were stratified by CKD stage (eGFR [mL/min/1.73 m2] by MDRD)
Stage 1, eGFR ≥90; stage 2, eGFR 60 to <90; stage 3, eGFR 30 to <60; stage 4, eGFR 15 to <30; stage 5 eGFR<15
SVR12 (ITT) rate was 98% overall, and high irrespective of CKD stage
Most total bilirubin elevations were primarily driven by indirect bilirubin and were not associated with ALT increase
Exposures of GLE and PIB were higher in patients with more advanced CKD, however PK changes
were not clinically relevant
Overall, the mean change in eGFR (mL/min/1.73 m2) from baseline to final post-treatment visit was
–2.5 ± 12.7
FRI-219, Nazario: Full Dose, Daily SOF Treatment in End-Stage Renal Disease:
FRI-219, Nazario: Full Dose, Daily SOF Treatment in End-Stage Renal Disease:
ESRD, end-stage renal disease. * 1 patient discontinued due to severe nausea; 1 patient discontinued due to sepsis from pneumonia unrelated to treatment.
Analysis of chronic HCV GT1–3 infected patients with ESRD on dialysis or
GFR <30 mL/min treated with full-dose (400 mg) SOF-based regimens
(SOF + SMV, LDV/SOF, SOF + DCV, SOF/VEL) for 12 or 24 weeks
Most frequent AEs were:
nausea (n = 4 [9%]), insomnia (n = 4 [9%], headache (n = 3 [7%]), pruritus (n = 1 [2%]), and anemia (n = 1 [2%])
The AE profile and rate of discontinuation were
similar to those in the general HCV population
n
N
No hepatic decompensation events
No dose adjustments
7% (3/45) of patients were not on dialysis
FRI-229, Kuo: No Adverse Renal Side Effects in Patients with Mild
FRI-229, Kuo: No Adverse Renal Side Effects in Patients with Mild
CKD-EPI, chronic kidney disease epidemiology collaboration; eGFR, estimated glomerular filtration rate;
EOT, end of treatment; MDRD, modification of diet in renal disease; PTW12, post-treatment Week 12; SCr, serum creatinine.
Real-world retrospective study of the effect of SOF on renal function in patients with baseline eGFR <60 mL/min/1.73 m2 and chronic HCV infection in Hawaii
Serum creatinine
Overall average increase in SCr of 0.04 from baseline to EOT
(p <0.01); there was no significant different in SCr
between EOT and PTW12 (p = 0.26)
In patients ≥65 years old, SCr increased on average by 0.05 during therapy (p< 0.01); no significant difference was
found between EOT and PTW12 (p = 0.45)
No significant difference in SCr between baseline, EOT, and
PTW12 in patients with renal impairment (p = 0.61)
GFR: baseline to EOT
Laboratory GFR: no significant difference in any eGFR subgroup
Cockcroft–Gault formula: average decrease of 4.72 (p <0.01) among patients with GFR >60
MDRD formula: average decrease of 5.18 (p <0.01) among patients with GFR >60
CKD-EPI formula: average decrease of 5.18 (p <0.01) among patients with GFR >60
GFR: EOT to PTW12
No significant difference when GFR was calculated by any of the GFR equations
THU-269, Theocharidou: Changes in Renal Function in Patients with Hepatitis C-Related
THU-269, Theocharidou: Changes in Renal Function in Patients with Hepatitis C-Related
CC, compensated cirrhosis; DC, decompensated cirrhosis; eGFR, estimated glomerular filtration rate;
EOT, end of treatment; MDRD, modification of diet in renal disease equation; NGAL, neutrophil gelatinase-associated lipocalin; PTW12, post treatment week 12.
* Renal risk factors include pre-existing renal impairment, diabetes mellitus, hypertension, and diuretics.
Assessing changes in renal function during DAA (mostly SOF) therapy in HCV-infected patients with compensated or decompensated cirrhosis using conventional markers (creatinine and eGFR using MDRD) and serum biomarkers (NGAL and cystatin C)
A poor correlation between NGAL or cystatin c and eGFR or creatinine existed
Impairment of renal function (detected by serum biomarkers) occurred during treatment in both groups and persisted beyond EOT
No difference in baseline creatinine or eGFR between CC and DC patients
No difference in eGFR between baseline
and EOT
No significant changes in creatinine
or eGFR
SAT-297, Younossi: EBR/GZR Effectiveness in Patients with Chronic HCV and Chronic
SAT-297, Younossi: EBR/GZR Effectiveness in Patients with Chronic HCV and Chronic
CKD, chronic kidney disease; PP, per-protocol (defined as patients that completed intended therapy and received SVR testing at 12 weeks); VF, virologic failure.
* eGFR values were calculated using the CKD-EPI Creatinine equation; † Includes GT1 unknown, GT2, GT3, and GT unknown.
Data from the TRIO Network were used to evaluate the real-world effectiveness of EBR/GZR in patients with CKD* (baseline eGFR <90 mL/min/1.73 m2) in the United States
440 patients treated with EBR/GZR; 261 with CKD (24% stage 2, 20% stage 3, and 53% stage 4–5
EBR/GZR was used in 93% of patients with 7% receiving RBV. Most patients were treated for 12 wks.
1
1
34
36
27
27
11
11
68
68
142
144
CKD stage
PP population (n = 144)
2 VF
n
N
Other Populations
Other Populations
Executive Summary
Summary:
It appears to be a question as to whether
Executive Summary
Summary:
It appears to be a question as to whether
High SVR rates (>98%) were observed in special populations (HIV/HCV coinfected, post-transplant) treated with G/P with minimal drug-drug interactions anticipated to require additional patient monitoring requirements. No new safety signals were observed and the SVR rates were high regardless of patient or viral characteristics
HIV/HCV coinfected and patients post-transplant treated with G/P are not expected to require treatment durations that differ from TN NC or TN C patients
A pangenotypic regimen like G/P that can deliver high SVR rates with the shortest treatment durations available should provide additional benefits, especially for difficult to treat patient populations (i.e. GT3)
PWIDs achieved high SVR rates with DAAs despite challenges to adherence. These patients may benefit from shorter courses of treatment, as adherence was noted to decline with extended therapy duration
TN NC, treatment-naïve, non-cirrhotic; TN C, treatment-naïve with compensated cirrhosis.
LBP-522, Rockstroh: Efficacy and Safety of G/P in Patients Co-infected with
LBP-522, Rockstroh: Efficacy and Safety of G/P in Patients Co-infected with
BT, breakthrough; d/c, discontinuation; mITT, excludes non-virologic failure.
* No GT5 were enrolled; † Patient achieved SVR4, but was lost to follow-up;
‡ Cerebrovascular accident and cerebral haemorrhage; both unrelated to G/P.
Phase 3, multicenter study evaluating G/P treatment in HCV/HIV-1 co-infected patients for 8 weeks (non-cirrhotic) or 12 weeks (cirrhotic) in HCV/HIV co-infected patients with HCV GT1–6 infection
SVR12 was 100% (136/136) in patients without cirrhosis treated for 8 weeks
SVR12 (mITT) was 93% (14/15) in patients with cirrhosis
1 patient with GT3a infection and cirrhosis had on-treatment failure at Week 8
No NS3 RASs at baseline; Y56H at failure
NS5A A30V at baseline; S24F, M28K at failure
LBO-03, Reau: MAGELLAN-2: Safety and Efficacy of G/P in Liver or
LBO-03, Reau: MAGELLAN-2: Safety and Efficacy of G/P in Liver or
Phase 3 study to evaluate the efficacy and safety of G/P for 12 weeks in adults with chronic HCV GT1–6 infection without cirrhosis who have had liver (n = 80) or renal (n = 20) transplant
Grade 3 laboratory abnormalities were rare
Patient with mild liver transplant rejection unrelated to DDIs and did not lead to treatment interruption
GT: 1 (57%), 2 (13%), 3 (24%), 4–6 (6%)
Fibrosis: F0–1 (80%), F2 (6%), F3 (14%)
BL immunosuppressant medication:
tacrolimus (68%), mycophenolic acid (30%), cyclosporine (13%), prednisone (13%), prednisolone (11%), everolimus (8%), azathioprine (6%), and sirolimus (7%)
PS-130, Litwin: PREVAIL: Intensive Models of HCV Care for People Who
PS-130, Litwin: PREVAIL: Intensive Models of HCV Care for People Who
OAT = Outcomes, Adherence, Treatment; TAU = Individual self-administered treatment; DOT = directly observed treatment; * Reasons for treatment withdrawal include
not interested in HCV treatment, and no longer in OAT; † Any drug use includes use of any drugs in 6 months, including opiates, cocaine and benzodiazepines; ‡ 3 patients did not achieve
undetectable HCV RNA, 2 patients died, 4 patients with HCV RNA not detected at EOT.
PWIDs with HCV GT1 were randomized to one of three models of HCV care delivered on-site in an OAT program. Adherence measured by electronic blister pack
Adherence rates %
Study weeks
1–2
3–4
5–6
7–8
9–10
11–12
Overall adherence:
Individual: 74%
Group: 78%
DOT: 83%
Overall SVR12 rate was 94%‡
Individual: 90% (46/51)
Group: 94% (48/51)
DOT: 98% (50/51)
On-site DAA treatment as highly effective among PWIDs receiving OAT despite active drug use and comorbidities
Intensive care models led to higher rates of adherence
FRI-234, Grebely; The SIMPLIFY Study: Efficacy and Safety of SOF/VEL in
FRI-234, Grebely; The SIMPLIFY Study: Efficacy and Safety of SOF/VEL in
A phase 4, open-label, single arm, multicenter, international trial of SOF/VEL for 12 weeks in n = 103 patients with HCV infection and recent injection drug use.
* At study screening; † Missing data in n = 8 patients.
No cases of virologic failure, n = 1 virologic relapse/re-infection to date
3 LTFU
1 death
DDIs and PK
DDIs and PK
Executive Summary
Data presented at EASL allowed for a better understanding of
Executive Summary
Data presented at EASL allowed for a better understanding of
For certain classes of medications, G/P will have a more competitive DDI profile than SOF/VEL/VOX. In statins, for example, SOF/VEL/VOX may have a more challenging DDI profile
The actual number of DDIs will be confirmed in the pending label; the main classes of interactions are similar to GLE
FRI-187, Garrison: Drug-Drug Interaction Profile of SOF/VEL/VOX Fixed-Dose Combination
ARVs, antiretrovirals; ATV,
FRI-187, Garrison: Drug-Drug Interaction Profile of SOF/VEL/VOX Fixed-Dose Combination
ARVs, antiretrovirals; ATV,
The DDI profile of SOF/VEL/VOX with drug transporter and CYP probes, and commonly used concomitant medications was characterized using Phase 1 clinical data
SOF/VEL/VOX 400/100/100 mg (+ VOX 100 mg when evaluating perpetrator interactions to approximate systemic VOX exposures observed in HCV-infected patients) was administered to healthy volunteers
Strong OATP inhibitors increased VOX exposures
Inducers of P-gp, BCRP, and/or CYPs decreased SOF, VEL, and/or VOX exposures
Sensitive substrates of P-gp, BCRP, or OATP1B1/1B3 may require dose adjustment or use with caution and/or monitoring
Clinically significant interactions with HIV ARVs limited to EFV, ATV and lopinavir
Real World Evidence
Real World Evidence
Executive Summary
RWE continues to confirm the results of clinical trials across
Executive Summary
RWE continues to confirm the results of clinical trials across
First real-world data confirms the effectiveness of EBR/GZR in patients with and without chronic kidney disease
Advanced fibrosis and presence of cirrhosis continue to be a predictor of lower SVR rates
LDV/SOF use may be expanded based on RWE data suggesting HCV RNA BL VL >6 million has no impact on SVR
It will be important to show that the presence of baseline characteristics (especially patients with advanced liver fibrosis) have no impact on SVR rates in patients treated with G/P in the real world
SAT-244, Tsai: Utilization of DAA therapies LDV/SOF and SOF/VEL in Patients
SAT-244, Tsai: Utilization of DAA therapies LDV/SOF and SOF/VEL in Patients
PP, Per protocol; TE, treatment experienced; TN, Treatment-naive.
Real-world study to evaluate utilization of LDV/SOF (n = 1327) and SOF/VEL (n = 89) in
HCV GT1-infected patients. Data were collected through Trio Health’s Innervation Platform
in the US in 36 states and predominantly in community practices
PP SVR12 (%)
147
151
282
288
23
24
39
41
91
92
5
5
177
183
255
259
20
20
12
12
120
122
9
10
183
189
321
327
6
6
61
62
10
11
Baseline characteristics of patients were similar between 12 week LDV/SOF and 12 week SOF/VEL groups, with the exception of prior TE (17% [159/949] 12 weeks LDV/SOF vs. 31% [28/89] SOF/VEL, p <0.001) and platelets <100,000/mL (9% [72/803] 12 weeks LDV/SOF vs. 18% [14/78] SOF/VEL, p = 0.011)
19
19
n
N
Overall SVR12 (PP)
LDV/SOF (8 weeks): 97% (189/195)
LDV/SOF (12 weeks): 98% (382/389)
SOF/VEL (12 weeks): 97% (29/30)
Among patients treated with LDV/SOF for 8 weeks, those treated in community settings were more likely to achieve SVR than those treated in academic settings
(p = 0.026; 98% vs 88%)
SAT-222, Khalili: Safety and Efficacy of SOF/VEL ± RBV for the
SAT-222, Khalili: Safety and Efficacy of SOF/VEL ± RBV for the
*SVR presented for patients with available virological outcomes, excluding patients
who d/c early except for whom lack of efficacy was recorded.
Real-world efficacy and safety of SOF/VEL +/- RBV for 12 weeks in treatment-naive or -experienced HCV GT1-6 patients in the HCV-TARGET registry
Patients who did not achieve SVR were mainly treatment experienced and/or had advanced liver disease
SVR4/12*
PS-102, Curry: Utilization of SOF/VEL in GT2–6 HCV: Real-World Experience from
PS-102, Curry: Utilization of SOF/VEL in GT2–6 HCV: Real-World Experience from
PP, per-protocol (includes patients who completed treatment and excluded patients with non-virologic failure).
Real-world study of 1827 patients in the US HCV TRIO network to evaluate treatment utilization and compare outcomes between SOV/VEL ± RBV and existing DAA therapies in patients with GT2–6 chronic HCV
Prior to SOF/VEL approval in June 2016, the most commonly used regimens were SOF + RBV (77% in GT2),
DCV + SOF ± RBV (86% for GT3), and LDV/SOF ± RBV (90% in GT4–6)
After approval, SOF/VEL ± RBV was used in 81% of GT2 patients, 74% of GT3 patients, and 36% of GT4–6 patients
66
68
10
11
238
252
266
267
PP population
SOF/VEL ± RBV
SOF + RBV
DCV + SOF ± RBV
LDV/SOF ± RBV
SVR rates were similar to those observed in clinical trials
n
N
FRI-247, Vermehren: Use of the 6 Million Viral Load Cut-off to
FRI-247, Vermehren: Use of the 6 Million Viral Load Cut-off to
TN, treatment naive; NC, non-cirrhotic; BL VL, baseline viral load.
* Criteria for 8-week LDV/SOF ± RBV treatment.
*
DHC-R: A prospective, multicentre, real-world cohort study comprising ~10,000 HCV infected patients. This analysis includes HCV GT1-infected patients who received LDV/SOF ± RBV
for 8 (N = 981) or 12 (N = 1939) weeks
All patients with BL VL > 6M treated for 8 weeks achieved SVR
42 relapsers
4/42 (10%) had a BL VL >6M IU/mL (all were treated for 12 weeks)
12/42 (29%) had been treated for 8 weeks and all had BLVL <6M IU/mL
BL VL < 6M
SVR12 (%)
LDV/SOF ± RBV
8 Weeks
LDV/SOF ± RBV
12 Weeks
793
807
23
23
1429
1463
209
214
n
N
BL VL < 6M IU/mL
BL VL > 6M IU/mL
FRI-239, McCombs: Analysis of the Real-World Treatment Effectiveness of EBR/GZR
HCC, hepatocellular
FRI-239, McCombs: Analysis of the Real-World Treatment Effectiveness of EBR/GZR
HCC, hepatocellular
* Reference group = treatment-naive patients
A real-world, retrospective, cohort study to evaluate the effectiveness of EBR/GZR
in HCV-infected patients within the Veterans Health Administration
Patients who received RBV (OR 0.31 (95% CI, 0.20–0.49);
p < 0.0001) and treatment-experienced patients*
(OR 0.61 (95% CI, 0.40–0.92); p = 0.02) were less likely to achieve SVR12
FIB4 > 3.25 (OR 0.73 (95% CI, 0.41–1.29);
p = 0.28) demonstrated a trend towards being a negative predictor of SVR12
1924
2069
247
266
178
197
36
41
13
16
383
408
912
971
373
410
1850
1989
56
60
201
242
1559
1659
360
410
n
N
SVR12 (%)
THU-237, Pearlman: Safety and Efficacy of EBR/GZR ± RBV for the
THU-237, Pearlman: Safety and Efficacy of EBR/GZR ± RBV for the
BL, baseline; C, cirrhosis; GT1 nos, not defined in abstract;
NR, non-responder; PP, per protocol (excludes non-virologic failures); RL, relapse; TE, treatment-experienced; TN, treatment-naive.
Analysis of HCV GT1-infected patients treated with EBR/GZR ± RBV in the real-world HCV-TARGET study at academic and community medical centres in Europe and North America
RBV added in <10% of patients, and mainly limited to those with baseline RASs and those who are TE or cirrhotic
Anemia was reported in 2/200 treated with EBR/GZR alone and 1/16 treated with EBR/GZR + RBV
AEs leading to d/c:
Depression n = 1; Drug intolerance n = 1
SAT-297, Younossi: EBR/GZR Effectiveness in Patients with Chronic HCV and Chronic
SAT-297, Younossi: EBR/GZR Effectiveness in Patients with Chronic HCV and Chronic
CKD, chronic kidney disease; PP, per-protocol (defined as patients that completed intended therapy and received SVR testing at 12 weeks); VF, virologic failure.
* eGFR values were calculated using the CKD-EPI Creatinine equation; † Includes GT1 unknown, GT2, GT3, and GT unknown.
Data from the TRIO Network were used to evaluate the real-world effectiveness of EBR/GZR in patients with CKD* (baseline eGFR <90 mL/min/1.73 m2) in the United States
440 patients treated with EBR/GZR; 261 with CKD (24% stage 2, 20% stage 3, and 53% stage 4–5
EBR/GZR was used in 93% of patients with 7% receiving RBV. Most patients were treated for 12 wks.
1
1
34
36
27
27
11
11
68
68
142
144
CKD stage
PP population (n = 144)
2 VF
n
N
THU-239, Bacon: Real-World Use of EBR/GZR and Outcomes in Patients with
THU-239, Bacon: Real-World Use of EBR/GZR and Outcomes in Patients with
BL VL, baseline viral load; CKD, chronic kidney disease; LTFU, lost to follow-up; PP, per protocol; RAS, resistance associated substitution;
TE, treatment experienced; TN, treatment naive.
*GT2 n=2, GT3 n=1, GT unknown n=21; † Of the 4 TE F4 patients who did not achieve SVR, prior treatments were LDV/SOF, SMV + SOF, pegIFN + RBV and unknown.
Retrospective analysis of HCV-infected patients treated with EBR/GZR and a HCV GT1-infected comparator group treated with non-EBR/GZR regimens in the real-world TRIO Health Network
90% of the observed EBR/GZR use was for
12 weeks without RBV and mostly in
GT1-infected patients
PP population
Sat-279, Flamm: Real-World Treatment Utilisation and Results in the Renaissance of
Sat-279, Flamm: Real-World Treatment Utilisation and Results in the Renaissance of
CKD, chronic kidney disease; ITT, intent to treat.; d/c, discontinuation; TE, treatment experienced; LTFU, lost to follow-up.
Retrospective analysis of HCV-infected patients in the real-world TRIO Health Network treated with DAA regimens October 2015–October 2016 (N = 8955)
1% died
7% LTFU
3% d/c
1% died
8% LTFU
5% d/c
1% died
5% LTFU
6% d/c
1% died
6% LTFU
1% d/c
SVR12 failures and d/c rates were higher with use of non-preferred therapies,
for TE patients and patients with cirrhosis
N = 4491
N = 524
N = 480
N = 213
THU-284, Maunoury: Cost-Effectiveness of EBR/GZR Regimen for Treating HCV GT1 Infection
THU-284, Maunoury: Cost-Effectiveness of EBR/GZR Regimen for Treating HCV GT1 Infection
CKD, chronic kidney disease; LY, life years; QALY, quality-adjusted life years.
A decision-analytic model using both medical and economic criteria was used to estimate the cost-effectiveness of EBR/GZR vs no treatment (standard of care) in patients with HCV GT1 infection and CKD stage 4–5 (creatinine clearance <30 mL/min/1.73 m2, including hemodialysis patients)
The model was designed to identify the best strategy from an ‘all payers’ perspective
Sensitivity analysis shows that key drivers are:
Risk of CKD progression
Average annual cost of kidney transplant
Risk of death from HCV
Probabilistic sensitivity analysis suggests that EBR/GZR is increasingly more effective than standard of care in CKD patients, but also more expensive
100% of incremental cost-utility ratio simulations were < €31,500
PS-096, Deterding: Long-Term Follow-Up After IFN-Free Therapy of Advanced HCV-Associated Liver
PS-096, Deterding: Long-Term Follow-Up After IFN-Free Therapy of Advanced HCV-Associated Liver
HCCs, hepatocellular carcinoma; PIs, protease inhibitors.
*Clinical events defined as defined by increase in MELD by ≥3 points, variceal bleeding, ascites,
encephalopathy, liver transplantation, de novo HCC, or death.
Analysis of DAA treatment in HCV-infected patients with advanced liver cirrhosis in the DHC-R – a large, multicenter, real-world cohort in Germany
121 (11%) patients reported SAEs
63 SAEs were liver-related; HCC (n = 17), variceal bleeding (n = 19), and ascites (n = 4)
14 deaths; 10 were liver-related
Child-Pugh B or C were associated with clinical events*
Liver function improved in the majority of patients
during and after treatment
Neither use of HCV PIs nor RBV were associated clinical events*
Criteria for advanced liver cirrhosis included at least one of the following:
FibroScan >20 kPa, platelets <90,000/μL, albumin <35 g/L or clinical signs of liver decompensation
Liver function improvement – ALT and platelets
Liver function improvement – bilirubin and albumin
BL albumin 35.9 ± 8.5 g/L
BL bilirubin 1.1 ± 0.8 mg/dL
BL platelets 106.0 ± 56.7 x 103/µL
BL ALT 99.1 ± 69.8 U/L
SAT-229, Sulkowski: Incidence of and Predictors for DAA Treatment Failure Among
SAT-229, Sulkowski: Incidence of and Predictors for DAA Treatment Failure Among
d/c, discontinuation; IPW, inverse probability weighting.
Analysis of the incidence and predictors of virologic failure as well as re-treatment outcomes in HCV GT1-infected patients treated with ≥2 DAAs in the real-world HCV TARGET cohort
91
2241
IPW analysis
Compared to SMV + SOF ± RBV patients, LDV/SOF ± RBV (OR 2.63; p < 0.01) and OBV/PTV/r + DSV ± RBV
(OR 1.92; p < 0.01) patients were more likely to achieve SVR
130
1107
38
751
To date, 19/22 (86%) DAA failures retreated with LDV/SOF ± RBV or OBV/PTV/r + DSV ± RBV achieved SVR
Of 4099 GT1-infected patients treated with ≥ 2 DAAs, 259 (6%) experienced treatment failure (primarily as relapse)
n
N
Cirrhosis, low albumin/platelet, high total bilirubin, and male sex were associated with treatment failure at the p < 0.001 level
42 d/c due to AEs
FRI-280, Kondili: Clinical Characterization and Economic Impact Evaluation of
Anti-HCV DAA
FRI-280, Kondili: Clinical Characterization and Economic Impact Evaluation of Anti-HCV DAA
HCC, hepatocellular carcinoma.
An analysis of DAA treatment failure and its clinical and economic burden
using data from HCV-infected patients in the PITER study cohort
Of 3926 patients who underwent DAA treatment, 4% (n = 140) failed to achieve SVR12
Clinical burden of DAA failure
HCC occurred in 6 (5%) patients at end of treatment and in 10 patients (8%) after
6-months' follow-up
5 patients with cirrhosis underwent transplant
CP class changed from A to B in 15 (12%) patients and from B to C in 1 (1%) patient
24 patients experienced hepatic decompensation
Economic burden of DAA failure
Mean cost among non-hospitalized patients was €694/patient (main cost driver was laboratory tests)
Mean cost among hospitalized patients was €18607/patient (main cost driver was number of diagnostic procedures, after hospital admission costs)
Failure rate increased with higher degree of fibrosis at baseline
PS-097, Freeman: 94% SVR with Parallel Imported Generic DAA Treatment for
PS-097, Freeman: 94% SVR with Parallel Imported Generic DAA Treatment for
* GT2 results almost entirely DCV + SOF; – Not applicable.
Real-world evaluation of the efficacy and safety of legally imported generic DAAs (including SOF, LDV, DCV) across five treatment access programs in 88 countries worldwide
Aggregated results for the 4 cohorts.
Cohort 1 final results & Cohorts 2–4 interim results
Cohort 2: N = 226; GT1, 2, 3, 4, 5
Cohort 3: N = 263; GT1, 2, 3, 4, 6
Cohort 4: N = 224; GT1b, 2, 3
REDEMPTION-1
The negative predictors significantly associated with SVR were cirrhosis (p = 0.01) and HCV RNA detectable after Day 24 (p = 0.02)
No new AEs reported
Cohorts include the Australian access program REDEMPTION-1, and a large cohort from London (Cohort 1)
New Molecules
New Molecules
PS-153, Gane: Short duration treatment with AL-335 and odalasvir (ODV) ±
PS-153, Gane: Short duration treatment with AL-335 and odalasvir (ODV) ±
VBT = Viral Breakthrough
Dose finding study:
Inclusion criteria:
Fibrosis stage F0–F3
GT1 or 3 infection
Treatment naive
3DAA vs 2DAA in
GT1-infected patients
3DAA 8 vs 6 weeks in
GT1-infected patients
3DAA in
GT3-infected patients
SVR rate (%), 95% CI
SVR rate (%), 95% CI
SVR rate (%), 95% CI
AEs were mild and unspecific
1 d/c due to AE
4 Relapse
1 VBT
5 Relapse
1 VBT
2 Relapse
AL-335 + ODV ± SMV 6 or 8 weeks achieved high SVR in non-cirrhotic GT1 patients
OBV/PTV/r + DSV
OBV/PTV/r + DSV
Executive Summary
Real world results
confirm safety and effectiveness of 2D and 3D
Executive Summary
Real world results
confirm safety and effectiveness of 2D and 3D
demonstrate improvement in perceived burden of disease and work productivity/activity
Reiterate that rates of hepatic decompensation and HCC in patients with advanced liver disease are similar to those seen in the literature
Treatment with 2D/3D demonstrates high SVR in patients with liver and renal transplant – with and without compensated cirrhosis
One death due to tacrolimus overdose [contraindicated in the USPI as of March 2017, and ‘not recommended’ in the EU label]
100% SVR12 [mITT] seen in first available pediatric data with 2D/3D ± RBV. The regimen was well tolerated by adolescents [12–17 yrs old] with no grade 3 or 4 laboratory abnormalities or treatment-emergent SAEs
Real world evidence of SOF-based regimens used in patients with severe CKD attempt to establish safety and effectiveness
Conflicting data presented on impact of SOF on eGFR
SAT-226, Londoño: Effectiveness, Safety/Tolerability of OBV/PTV/r ± DSV in Patients with
SAT-226, Londoño: Effectiveness, Safety/Tolerability of OBV/PTV/r ± DSV in Patients with
CKD, chronic kidney disease; EOT, end of treatment; PTW, post-treatment Week; VF, virologic failure. * Male patient with GT1b
HCV infection and CKD Stage 5 experienced VF with 12 weeks of treatment with OBV/PTV/r + DSV + RBV. Patient did not reach SVR12.
A non-interventional, retrospective, multi-center, real-world study of OBV/PTV/r ± DSV ± RBV in
n = 135 HCV GT1- or 4-infected (14/135 [10%] HIV/HCV co-infected patients) with CKD stages
IIIb–V in 31 centers in Spain
125
126
n
N
11 (8%) patients had severe AEs
Most AEs were mild or moderate in severity
5 (4%) patients withdrew treatment
Most patients (94% [33/35]) did not have a clinically significant decrease in CKD Stage IIIb and IV baseline eGFR levels at EOT or PTW12 in any CKD stage group
26% of GT1-infected patients received OBV/PTV/r + DSV + RBV
80% of GT4-infected patients received OBV/PTV/r + RBV
111
112
14
14
13
13
19
19
93
94
HIV/HCV co-infection
CKD stage
1 VF*
GT/Regimen
Renal transplant
115
116
10
10
76
77
49
49
FRI-267, Agarwal: CORAL-I (Cohorts 3–6): Safety and Efficacy of OBV/PTV/R ±
FRI-267, Agarwal: CORAL-I (Cohorts 3–6): Safety and Efficacy of OBV/PTV/R ±
C, cirrhosis; d/c, discontinuation; LT, liver transplant; RAS, resistance-associated substitution; RT, renal transplant.
An ongoing, phase 2, open-label study evaluated OBV/PTV/R ± DSV ± RBV in HCV GT1-infected patients with liver or kidney transplant and HCV GT4-infected patients with liver transplant
6
6
Compensated cirrhosis
Non-cirrhotic
Death was due to tacrolimus overdose
n
N
33
34
9
12
3
3
3 d/c due to AE
1 relapse
Patients were treatment-naive or IFN-experienced receiving tacrolimus or cyclosporine
HCV GT1
HCV GT4
Relapse patient had treatment-emergent RASs D168V in NS3 and Q30R in NS5A
There were 3 study drug related SAEs (nausea and vomiting, acute respiratory failure, and tacrolimus overdose), and led to d/c of study drug
Grade 3 laboratory abnormalities were rare, and there were no grade 4 events
± Cirrhosis
THU-251, Leung: ZIRCON: Pharmacokinetics, Safety, and Efficacy of OBV/PTV/r ± DSV
THU-251, Leung: ZIRCON: Pharmacokinetics, Safety, and Efficacy of OBV/PTV/r ± DSV
CV, coefficient of variation; d/c, discontinuation; EOT, end of treatment;
PK, pharmacokinetics.* N = 11 for AUC and Ctrough of OBV and PTV;
† AUC0–24 hours for OBV and PTV, AUC0–12 hours for DSV; ‡ as assessed by investigator.
An two-part, ongoing, open-label, phase 2/3 study assessed the PK of OBV/PTV/r + DSV ± RBV in GT1-infected adolescents without cirrhosis (Part 1) and the efficacy and safety of
OBV/PTV/r ± DSV ± RBV in GT1- or GT4-infected adolescents with or without cirrhosis (Part 1 and 2)
Preliminary PK results: Geometric means from Part 1 (N = 12)*
No confirmed grade 3 or 4 laboratory
abnormalities were reported
38
38
n
N
DAA exposures were comparable to historical results seen in adults
FRI-269, Buggisch: Effectiveness, Safety and Quality of Life in Patients Treated
FRI-269, Buggisch: Effectiveness, Safety and Quality of Life in Patients Treated
QoL, quality of life.
LIFE-C: German observational study assessing effectiveness, safety, and health-related QoL
in patients treated with OBV/PTV/r ± DSV ± RBV according to local label,
using several health-related QoL questionnaires (N = 472)
Study populations were: Core (excluded patients who had not begun treatment and those without confirmed on-label treatment) and Subgroup (excluded those who received 24-week therapy or began treatment after the cut-off date)
59
61
148
150
22
24
113 AEs occurred in 66 patients
Fatigue, pruritus, and rash were the most common AEs
96% (215/225) of treated patients in the subgroup population achieved adherence rates ≥ 95%
n
N
Core population
FRI-250, Lubel: Very High Real-World Efficacy of OBV/PTV/r + DSV ±
FRI-250, Lubel: Very High Real-World Efficacy of OBV/PTV/r + DSV ±
C, cirrhotic; CPA/B, Child-Pugh A/B; HCC hepatocellular carcinoma; NC, non-cirrhotic; NR, not reported.
* Variceal hemorrhage n = 4; hepatic encephalopathy n = 5; ascites n = 1; spontaneous bacterial peritonitis n = 1; unspecified cause n = 1;
† 7 patients had CPA cirrhosis and 1 patient had CPB cirrhosis; 5 were de novo HCC; ‡ Hospital admission due to hepatic decompensation n = 7.
Real-world study of OBV/PTV/r + DSV ± RBV in HCV
GT1-infected patients at 20 centers in Australia (N = 451)
SAEs occurred in 35% (12/34) of CPB patients and 12% (36/306) of CPA patients (p = 0.0005)
In multivariate analysis, CPB was a significant predictor of SAEs (OR 7.2 [95% CI, 1.5–33.9]; p = 0.012)
In multivariate analysis, baseline bilirubin (OR 0.96,
p = 0.015) and early cessation (OR 0.04, p < 0.0001)
were significant factors related to SVR
n=451
n=111
n=340
n=NR
n=NR
THU-277, Sanai: 100% Efficacy to OBV/PTV/r ± DSV ± RBV in
THU-277, Sanai: 100% Efficacy to OBV/PTV/r ± DSV ± RBV in
CKD, chronic kidney disease; d/c. discontinuation; TN, treatment naive,
TE, treatment experienced; NC, non cirrhotic; C, cirrhotic .
* <15 mL/min/1.73 m2 by MDRD; ‡ Patient d/c study drugs at Week 4 and went on to achieve SVR12; § Deaths were due to
myocardial infarction (n = 1) and sepsis-related complications (n = 1); both were considered unrelated to study drugs.
SOLID registry: an ongoing observational, cohort study, evaluating real-world safety and efficacy of OBV/PTV/r ± DSV ± RBV for 12 or 24 weeks in HCV GT1- or 4-infected patients with severe CKD* on hemodialysis
Patients receiving RBV were more likely to have higher hemoglobin levels, GT1a and be TE
SAT-239, Alkadi: Decline in eGFR in HCV-Infected Patients While on Treatment
SAT-239, Alkadi: Decline in eGFR in HCV-Infected Patients While on Treatment
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate estimated using the CKD-EPI equation; IQR, interquartile range.
* Cirrhosis was calculated by FIB-4 score > 3.5.
The ERCHIVES cohort of HCV-infected US veterans was used to evaluate declines in eGFR during treatment with LDV/SOF ± RBV or OBV/PTV/r + DSV ± RBV by baseline kidney function
Percentage of patients with decline
in eGFR of > 10 mL/min/1.73 m2
Small number of
CKD 4–5 patients
Patients with ≥ 2 eGFR values 3 months apart prior to baseline and ≥ 1 eGFR value ≥ 12 weeks after baseline were included in the analysis
Extrahepatic Manifestations
Extrahepatic Manifestations
Executive Summary
Accumulating evidence for cyroglobulinemia, cardiovascular events and infertility/pregnancy outcomes provide
Executive Summary
Accumulating evidence for cyroglobulinemia, cardiovascular events and infertility/pregnancy outcomes provide
SAT-216, Sanchez-Gonzalez: The Cumulative Prevalence and Incidence of Extra-Hepatic Manifestations in
SAT-216, Sanchez-Gonzalez: The Cumulative Prevalence and Incidence of Extra-Hepatic Manifestations in
OptumTM Claims Data - ClinformaticsTM Data Mart dataset was used to evaluate the prevalence and incidence of 20 EHMs (including CKD, CVD, and metabolic- and immune-mediated diseases) in HCV-infected and non-HCV-infected patients in the United States
Two cohorts of adult patients with ≥5 years of post-index follow-up were matched 1:1 on age, sex, region, and years of follow-up: HCV and no-HCV (both N = 4032)
Cumulative incidence from 2nd to 5th year post-index for any EHM
HCV: 65%
Non-HCV: 48%
(OR = 2.1; p < 0.05)
Prevalence of CKD among HCV versus no-HCV cohorts in the 5th year post-index
HCV: 10.7%
Non-HCV: 4.4%
(OR = 2.6)
*P < 0.05
Cumulative prevalent and incident cases of any EHM from the 1st to the 5th year post-index
PS-099, Saadoun: VASCUVALDIC 2 study: SOF + DCV for
HCV-cryoglobulinemia vasculitis
PS-099, Saadoun: VASCUVALDIC 2 study: SOF + DCV for HCV-cryoglobulinemia vasculitis
Open label study of SOF (400 mg/day) + DCV (60 mg/day) for 12 or 24 weeks
1
PS-099, Saadoun: VASCUVALDIC 2 study: SOF + DCV for HCV-cryoglobulinemia vasculitis
PS-099, Saadoun: VASCUVALDIC 2 study: SOF + DCV for HCV-cryoglobulinemia vasculitis
Open label study of SOF (400 mg/day) + DCV (60 mg/day) for 12 or 24 weeks
Outcome of kidney parameters
Immunological response kinetics of cryoglobulinemia and C4
DAAs improve mixed cryoglobulinemia however longer follow up is needed
Purpura, skin ulcers and arthralgia
disappeared in all cases
Kidney involvement improved in 5/5
complete renal response in 4/5
Cryoglobulin level decreased from 0.56 ± 0.18 to 0.21 ± 0.14 g/L (W0 vs W36)
Cryoglobulin disappeared in 50%
C4 serum level increased from 0.08 ± 0.02 to 0.14 ± 0.02 g/L (W0 vs W36)
2
PS-032, Cacoub: The Cumulative Prevalence and Incidence of Extra-Hepatic Manifestations in
PS-032, Cacoub: The Cumulative Prevalence and Incidence of Extra-Hepatic Manifestations in
Predictors of MACE in patients with compensated HCV-related cirrhosis Multivariate Cox proportional hazards model
Patients enrolled/prospectively followed up from 2006–2012 with: a) biopsy-proven HCV cirrhosis;
b) CP A; c) +ve viremia; d) no prior liver complication. All patients received HCV treatment after inclusion
At endpoint, a SVR was noted in 4 (6.9%) who did vs
302 (37.8%) pts who did not present a MACE
(HR = 0.39 [0.13; 0.95], p =0.036)
MACE included stroke, myocardial infarction, ischemic heart disease, heart failure, peripheral arterial disease, cardiac arrest, and CV death
7% (62/878) of patients had total of 79 MACE
after a median f/u of 57.5 months
Overall survival at 5 years was 60% vs 88% in
those who did/did not have a MACE (p < 0.001)
Causes of death in patients who had a MACE mainly related to cardio-vascular disease in 32% (7/22) cases, liver failure 23% (n = 5) and HCC 14% (n = 3)
SVR12 was considered a time-dependent
covariate and associated with reduced rate of cardiovascular events
There is insufficient data from DAA era to compare differences between IFN-based and IFN-free therapy
SAT-217, Villa: Extra-hepatic manifestations from hepatitis C virus infection related to
SAT-217, Villa: Extra-hepatic manifestations from hepatitis C virus infection related to
US Insurance Claims Data from 2000-2015 was used to assess the relationship between HCV infection and female infertility and pregnancy outcomes in a large real-world population in the United States (US)
Rates of Adverse Pregnancy Outcomes
HEOR
HEOR
Executive Summary
Screening younger age cohorts will increase overall costs but is
Executive Summary
Screening younger age cohorts will increase overall costs but is
AbbVie needs to continue to reinforce the potential benefits of early screening and diagnosis and communicate the added costs associated with cohort or risked based screening approaches
FRI-183, Barocas: Population Level Outcomes and Cost-Effectiveness of Expanding Guidance for
FRI-183, Barocas: Population Level Outcomes and Cost-Effectiveness of Expanding Guidance for
Dx, diagnosis; ICER, incremental cost-effectiveness ratio; QALYs, quality adjusted life years; SoC, standard of care (one-time testing of persons born 1945–1965).
* All strategies assumed continued targeted testing of people who inject drugs.
Monte Carlo simulation of HCV testing and treatment with SOF/VEL was used to assess population-level outcomes and cost-effectiveness of expanding guidance for age-based HCV testing in the US with 4 strategies
Findings were robust in sensitivity analysis that assessed the impact of treatment on cost, utility, and mortality
The 4 strategies* were: 1) current SoC; 2) one-time testing adults ≥40 years old;
3) one-time testing adults ≥30 years old; and 4) one-time testing adults ≥18 years old
Expanded HCV testing increased the number of HCV cases identified, linkage to care, treatment uptake and numbers cured
FRI-458, Rein: The Cost-Effectiveness of a One Time HCV Antibody Test
Followed
FRI-458, Rein: The Cost-Effectiveness of a One Time HCV Antibody Test Followed
BC, birth cohort 1945–1965; RB, risked-based; QALYs, quality-adjusted life years; Tx, treatment.
* Annual probabilities of HCV testing: 0.05 risk-based, 0.212 birth-cohort, and 0.212 universal; for HCV GT1–4, SVR rates were weighted averages based on clinical trial
and market share data; treatment costs were weighted averages based on listed wholesale acquisition costs and market share data; 3% annual discount rate was used;
† Compared with next most costly scenario; ‡ medical management costs; § Testing, treatment, and medical management costs.
Analysis of health outcomes and cost-effectiveness of no HCV testing or treatment, and 3 testing scenarios in the US: 1) risk-based (RB) testing; 2) birth-cohort (BC) testing (1945–1965) and RB testing; 3) universal testing of all adults aged ≥18 years in 2014
Simulation model*: health outcomes and costs for HCV RNA+ persons
unaware of their infection status in 2018 and followed until death or age 100
Universal testing decreased liver-related
morbidity and mortality
Universal testing would result in 1.2
million additional years lived compared
with the current US testing strategy
Implementing a one-time universal screening strategy at 18 years of age would lead to the largest benefit in terms of discounted incremental HCV-related costs and impact on QALYs
SAT-225, Buti: Cost-Effectiveness of Screening for HCV in Population Born Between
SAT-225, Buti: Cost-Effectiveness of Screening for HCV in Population Born Between
ICER, incremental cost-effectiveness ratio; LYG, life-years gained; QALY, quality-adjusted life years.
* Prisoners, people who inject drugs, HIV/HCV co-infected. A 3% discount was used; † SVR rates obtained from clinical trials; ‡ Lifetime horizon was considered and a 3%
discount rate was applied to costs and outcomes; § direct costs (2016 €) only were considered.
Study assessing the cost-effectiveness of HCV testing the Spanish population born 1956–1970 (birth cohort) versus screening only high-risk* individuals born 1956–1970 (current screening strategy)
A decision analysis model to establish the eligible population for screening and a Markov model to simulate disease progression from diagnosis were used; 82% of ≥F2 detected cases were assumed to be treated with DAAs†
At an efficiency threshold of €30,000 per QALY, screening of the Spanish population born 1956-1970 is cost effective vs current screening strategy
The screening strategy was applied to 5,915,645 people, with 1.9% diagnosed with chronic HCV
Diagnosis and Linkage to Care
Diagnosis and Linkage to Care
Executive Summary
There remains significant challenges in terms of screening, diagnosis, and
Executive Summary
There remains significant challenges in terms of screening, diagnosis, and
Alternative screening strategies may help to reduce some of these challenges and connect more patients to care; however, it is important to understand the dynamics and roadblocks of each individual health care system
Regimens such as G/P that simplify treatment decisions may have a positive impact on the number of patients that can be successfully diagnosed and connected to care
In order to successfully achieve SVR, we also need to address other points of the HCV care cascade
FRI-478, Udompap: An Alternative Screening Strategy for HCV Infection Among Americans
FRI-478, Udompap: An Alternative Screening Strategy for HCV Infection Among Americans
BBBC, baby boomer birth cohort.
* FIB-4 scores defined as Low (<1.45), Indeterminant (1.45–3.25), High (>3.25); † Abnormal ALT >45 in men and >30 in women
NHANES participants were stratified by FIB-4* score and ALT† levels and the prevalence of
HCV calculated for each stratum;
33,476 participants had complete laboratory data for FIB-4 calculation; 33,468 were tested for HCV
Evaluation of abnormal ALT and FIB-4 score as a trigger for HCV screening using data from the National Health and Nutrition Examination Survey (NHANES) 1999–2012
Prevalence of HCV infection was higher among BBBC than non-BBBC participants (3.3% vs 0.7%)
Among patients unaware of their HCV infection, 59% would be diagnosed if abnormal ALT or high FIB-4 scores were used as a trigger for screening; 35% of these individuals did not belong to the BBBC
Participants unaware of infection
Prevalence of positive HCV RNA (%)
Screening threshold
THU-189, Pratt: An Audit of Hepatitis C Screening and Referral Patterns
THU-189, Pratt: An Audit of Hepatitis C Screening and Referral Patterns
PTW12, post-treatment Week 12.
* DNA, did not attend.
Audit of HCV serology requests October 2015–September 2016 at York teaching hospital, UK, to determine if the launch of a specialist hepatology service improved screening, assessment, and treatment of HCV-infected patients
Screening to assessment pathway
HCV treatment has been started in 105 patients compared with 4 patients in 2013; 76 patients reached PTW12 and 95% achieved an SVR12
SAT-194, Wong: Low Rates of HCV Testing and HCV Awareness Among
SAT-194, Wong: Low Rates of HCV Testing and HCV Awareness Among
IV, inrtravenous. * Based on U.S. Preventative Services Task Force guidelines.
Prospective cohort study of HCV screening rates and awareness of prior HCV test results among high-risk individuals*
When offered HCV testing, > 80% of patients accepted,
64% of patients completed testing; All HCV positive patients were linked to care
HCV Screening and Awareness
Significant differences in acceptance of HCV testing by race (p<0.001), country of birth (p<0.01), BB cohort (p<0.05) and English speaking vs non-English speaking (p<0.01)
67% were high-risk for HCV (eligible for screening)
30% received prior HCV testing
30% were aware of prior testing
FRI-475, Scott: Reaching HCV Elimination Targets Requires Health System Interventions to
FRI-475, Scott: Reaching HCV Elimination Targets Requires Health System Interventions to
OST, opioid substitution therapy; PWID, persons who inject drugs.
Assessment of interventions required in Australia, a setting where all living persons with HCV have access to therapy, to reach WHO HCV elimination targets. A dynamic HCV transmission and liver disease progression model was used to test the following interventions:
1) scaling up primary care treatment delivery; 2) using biomarkers in place of liver stiffness measurement;
3) point-of-care HCV RNA testing; 4) testing of PWID on OST
Treatment scale-up alone was not enough to reach WHO elimination targets by 2030 as remaining infections were among PWID who were unaware of their infection, and could continue to transmit infection
Year
Required to achieve WHO HCV elimination targets
Increased testing of PWID
Annual HCV RNA testing as part of OST
Annual HCV incidence among PWID
Scaling up primary case treatment
+ using APRI to assess cirrhosis
+ point-of-care RNA testing
= $62 million in healthcare cost savings
by 2030
HBV Reactivation
HBV Reactivation
Executive Summary
Data on HBV reactivation after HCV DAA therapy are unlikely
Executive Summary
Data on HBV reactivation after HCV DAA therapy are unlikely
HBV/HCV coinfected patients require monitoring once they initiate HCV treatment although clinically significant reactivation is seen rarely
No need for prophylactic therapy
HBsAg- and HBcAg+ risk of reactivation is negligible
Liu, PS-098: 12 Weeks LDV/SOF is Safe and Effective in Patients
with
Liu, PS-098: 12 Weeks LDV/SOF is Safe and Effective in Patients with
* n = 1 patient changed HBsAg status between screening and baseline.
Taiwanese, open-label study to evaluate the efficacy and safety of LDV/SOF for 12 weeks in HCV/HBV coinfected patients with or without compensated cirrhosis.
Patients were not receiving HBV treatment at enrolment
Efficacy
5% (5/111) of patients had concomitant increase in ALT
2% (2/111) of patients started
HBV therapy
HBV DNA kinetics
Higher baseline HBV DNA
and ALT were associated
with up to 1 log10 increase in HBV DNA
LDV/SOF 12 weeks associated with asymptomatic HBV reactivation in 63% (70/111) of patients
No patient experienced clinical signs or symptoms of HBV reactivation
THU-144, Tang: Absence of Hepatitis B Reactivation Among Veterans with Serological
THU-144, Tang: Absence of Hepatitis B Reactivation Among Veterans with Serological
ALT, alanine aminotransferase; ULN, upper limit of normal.
* Patients with HIV coinfection or post solid organ transplant were excluded.
Retrospective analysis of HBV reactivation in 192 Veterans,
receiving HCV DAA therapy at the Baltimore Veterans Affairs Medical Center,
with evidence of previous HBV infection*
2 patients experienced ALT increase > ULN during treatment without HBV reactivation, both of which normalized without intervention
No HBV reactivation events were observed